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ent subsets of leukemic stem and progenitor cells might be
differentially targeted by CXCR4 is unknown. Next
leukemic blast mobilization in vitro was strictly time-
dependent in the murine model with a peak of circulating
APL blasts after three hours and return to baseline after 12
h. Furthermore, APL blast mobilization in an in vivo model
seems to be influenced by the respective microenviron-
ment since extramedullary blasts with exclusive intraperi-
toneal expansion were not shown to be circulating after
AMD3100 administration.9 Our case shows that even after
intensified ATO treatment due to relapsed APL, PML-
RARα negative PBSC can be obtained by using the com-
petitive CXCR4 antagonist AMD3100 to increase the
number of harvested cells. These cells proved not to be
contaminated by clonogenic APL cells allowing successful
autologous HSCT which induced prolonged remission
without further maintenance therapy.
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Premature termination codon mutations in the
von Willebrand factor gene are associated with
allele-specific and position-dependent mRNA
decay
Nonsense-mediated mRNA decay (NMD) is an intron-
dependent RNA-degradation pathway responsible for
depleting transcripts containing premature termination
codons (PTCs), presumably to control the synthesis of
truncated proteins, potentially deleterious to cells. PTC-
bearing (PTC+) mRNAs are unstable only when the PTC is
located more than 50-55 nucleotides upstream of the last
intron.1 However, not all genes undergo NMD. Among
coagulation genes, NMD was demonstrated for factors V,
XI, and XIII, whereas it was shown to be inactive for fib-
rinogen (FGA, FGG) and factor VIII (FVIII) genes (Online
Supplementary Table S1).
Von Willebrand factor (VWF) is a multimeric glycopro-
tein, synthesized by endothelial cells and megakaryocytes,
promoting both platelet adhesion to the subendothelium
at sites of vascular injury, and platelet-platelet interactions
in high shear-rate conditions. It also binds and stabilizes
FVIII.2
Quantitative VWF deficiency can be classified as partial
(VWD1) or complete (VWD3), whereas qualitative defects
(VWD2) are subdivided into four main types: VWD2A,
VWD2B, VWD2M, VWD2N.2
The aim of this study was to investigate whether PTC-
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Figure 1. PML-RARα specific PCR–M) marker, lane 1) before ATO
treatment, lane 2) G-CSF mobilized stem cells, lane 3) G-CSF +
AMD3100 mobilized stem cells. Lanes were processed to secure
clearness since other patient samples were performed routinely
in parallel. Graph: treatment course after relapse. Local irradia-
tion with 30 Gy starting December 2005 and 20 Gy starting in
April 2006. Black arrows indicate intrathecal application of lipo-
somal cytarabine. White arrows pointing upward indicate aphere-
sis #1 with G-CSF and apheresis #2 with G-CSF and AMD3100.
White arrow pointing downward indicates autologous SCT after
myeloablative conditioning with 12 Gy TBI and intravenous
cyclophosphamide. 
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Figure 1. Functional analysis of the effect of the c.2546+3G>C and
c.8155+6T>C splicing mutations on the VWF mRNA. (A, B) Top left:
In the box underneath the patient’s ideogram: patient’s VWD type
(in bold), VWF:Ag, VWF:RCo, and FVIII:C levels are listed. Top right:
Schematic representation of the VWF gene. Exons (boxes) and
introns (lines) are drawn to scale. The aberrant splicing event
observed in each patient (i.e. exon-19 and exon-50 skipping for
patients carrying the c.2546+3G>C or the c.8155+6T>C mutations,
respectively) is represented. The patient’s mutations are indicated
in the box above the gene scheme, with the splicing mutation in
bold. Mutation numbering is according to GenBank accession num-
bers NM_000552.3 (according to cDNA position) and
NP_000543.2 (native protein). Bottom left: RT-PCR products sepa-
rated on a 2% agarose gel. Lane M: molecular weight marker
(pUC8-HaeIII); other lanes (from left to right): RT-PCR products
amplified from total RNA extracted from patients’ platelets (plts)
and lymphocytes (lymph), and from platelet-derived RNA of a wild-
type individual (ctrl); lane NTC: no template control. Note: the exon-
19 skipped transcript was detectable only after a semi-nested PCR,
performed starting from 1 µL of the original RT-PCR product using
a specific primer spanning exons 18-20. Traces of the aberrantly-
spliced product were evidenced also in the wild-type sample, indi-
cating that this splicing is present also under physiological condi-
tions. Bottom right: Sequence electropherograms of RT-PCR prod-
ucts confirming the aberrant junction between exons 18/20
(c.2546+3G>C), panel A, and exons 49/51 (c.8155+6T>C), panel B. 
A
B
M ctrl plts lymph NTC
VWD2N
VWF:Ag 66 IU/dL
VWF:RCo 57 IU/dL
FVIII:C 35 IU/dL
VWD1
VWF:Ag 2 IU/dL
VWF:RCo <6 IU/dL
FVIII:C 27 IU/dL
c.8155+6T>C/c1927R
c.2546+3G>C/R854Q
M ctrl plts lymph NTC
wild type
exon-50
skipped
exon-19
skipped
skipped
heteroduplex
wild type
wild type/
exon-19
Stop after 24 aa
Stop after 14 aa
P1
P2
587
458
434
298
267
236
174
587
458
434
298
267
236
exon 18 exon 20
exon 49 exon 51
Figure 2. Missense mutations
and 1-bp deletion analyses. The
central panel shows a schemat-
ic representation of part of the
VWF gene (introns 18-21 and
introns 33-37; exons are repre-
sented by boxes, introns by lines,
and are not drawn to scale).
Panel (A) Electropherograms of
the regions surrounding the mis-
sense mutations sequenced on
the genomic DNA and on
platelet and lymphocyte cDNAs
of the 2 patients. The position of
the mutations is boxed. Panel
(B) left: Electropherograms of
the region surrounding the 1-bp
deletion obtained by sequencing
PCR-amplified fragments from
genomic DNA and on platelet
and lymphocyte cDNAs of P3.
Panel (B) right: GeneMapper
windows displaying fluorescence
peaks corresponding to wild-
type and mutant fragments
obtained from genomic DNA as
well as platelet and lymphocyte
cDNAs. The areas of the fluores-
cence peaks corresponding to
the mutant and wild-type PCR
fragments were measured by
the GeneMapper v4.0 software.
The X-axis represents
GeneMapper data points and
the Y-axis represents fluores-
cence units (FUs).
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introducing mutations in the VWF gene are associated
with NMD.
To this purpose, three unrelated Italian probands (P1-
P3), heterozygous for at least one truncating mutation,
were studied (Figure 1). Their main clinical characteristics
are listed in the Online Supplementary Table S2.
P1 has VWD2N and is compound heterozygous for the
previously reported R854Q mutation (c.2561G>A, exon
20)2 and the novel c.2546+3G>C splicing defect (intron
19). P2 has VWD1 caused by compound heterozygosity
for two novel mutations: C1927R (c.5779T>C, exon 34)
and c.8155+6T>C (intron 50). P3 is heterozygous for the
VWD3-causing c.6182delT mutation (exon 36).3
To evaluate the effect of the novel c.2546+3G>C and
c.8155+6T>C splicing mutations on VWF pre-mRNA pro-
cessing, cDNA regions spanning exons 18-21 and 49-52
were amplified by RT-PCR from platelet- and lymphocyte-
derived mRNA of each patient. Sequencing of RT-PCR
products demonstrated that c.8155+6T>C causes the skip-
ping of exon 50 (Figure 1B), leading to a PTC in exon 51
(for details on methods, see Online Supplementary
Appendix).
Concerning c.2546+3G>C, a product lacking exon 19
could be amplified and sequenced only after a second
semi-nested PCR (Figure 1A); this mutation would lead to
the introduction of a PTC in exon 20. A very low amount
of the same skipped transcript could be detected also in
the control individual, indicating the existence of a “phys-
iological” aberrant splicing event.
To investigate whether the two PTC-introducing splic-
ing defects are associated with mRNA degradation, a frag-
ment containing the relevant missense mutation was PCR
amplified from genomic DNA and from platelet and lym-
phocyte cDNAs of P1 and P2, and sequenced.
Concerning P1, the product obtained from genomic
DNA resulted heterozygous for R854Q, whereas platelet-
and lymphocyte-derived RT-PCR products were homozy-
gous for this missense substitution (Figure 2A), confirming
that the PTC+ allele was degraded. As for patient P2, the
C1927R mutation was detected in the heterozygous state
both on genomic DNA and on cDNA (Figure 2A), suggest-
ing that the PTC+ allele is not subjected to NMD, as
expected for a PTC located 23 bp upstream of the last
exon-exon junction.
Patient P3 was similar to P1 in that the genomic
sequence was heterozygous for the T deletion, whereas
the cDNA sequences appeared wild type (Figure 2B), sug-
gesting a selective degradation of the mutant transcript. To
calculate the extent of the PTC+ mRNA degradation, the
fragment containing the T deletion was also PCR ampli-
fied using a (6-Fam)-labeled primer. PCR reactions were
separated on an ABI-3130XL sequencer and the peak areas
measured by the GeneMapper v4.0 software. On genom-
ic DNA, the wild-type/mutant ratio was equal to ~1, as
expected. Conversely, a degradation of 91.2% and 86.1%
of the PTC+ mRNA was calculated in platelets and lym-
phocytes (Figure 2B).
To summarize, our data consistently demonstrate that
truncated VWF proteins are unlikely to be produced as a
result of mRNA degradation, a topic on which conflicting
data were reported in the literature.4-6 Moreover, we con-
firm that NMD susceptibility of VWF transcripts is PTC-
position dependent. Last but not least, we were able to
measure the extent of degradation of the c.6182delT tran-
script (~90%).
Given the effects of VWF inhibitors, i.e. ineffectiveness
of replacement therapy and anaphylactic reactions to
treatment,2 it would be important to establish if NMD
might be a modulator of inhibitor development.
Considering that some PTC-introducing mutations escape
degradation even in genes known to be targets of NMD7,8
it would be interesting to analyze a larger group of VWD3
patients with truncating mutations, to verify if mRNA
degradation represents a general rule for truncating muta-
tions in the VWF gene.
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